NCT06232252View on ClinicalTrials.gov

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

April 25, 2025

Study Completion Date

April 29, 2025

Conditions
Healthy
Interventions
DRUG

BI 765423

BI 765423

DRUG

Placebo matching BI 765423

Placebo matching BI 765423

Trial Locations (1)

2650

SGS Life Science Services - Clinical Research, Edegem

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06232252 - A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men | Biotech Hunter | Biotech Hunter